This article was originally published in The Tan Sheet
Recruitment underway for four-year Oregon Health Sciences University study examining standardized ginkgo biloba extract's effects in preventing or delaying cognitive decline in people ages 85 and older. Randomized, double-blind trial is enrolling 200 cognitively healthy subjects who will be followed for mild cognitive impairment, a precursor to dementia. Subjects will be randomized to either placebo or 240 mg ginkgo extract per day. Placebo subjects will be placed on ginkgo 24 months after entry. Changes in MRI-determined volume will be assessed at baseline, 24 and 42 months. Principal investigator is Jeffrey Kaye, MD, director of OHSU's Oregon Aging & Alzheimer's Disease Center. OHSU received $7.8 mil. from NCCAM for neurological disorders research in 1999 (1"The Tan Sheet" Oct. 4, 1999, p. 4)
You may also be interested in...
The National Center for Complementary & Alternative Medicine is sponsoring a multicenter study to test the safety, efficacy and tolerability of ginkgo biloba for the prevention of dementia in the elderly, the center announced Sept. 30.
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
Perrigo promotes in pricing, planning